Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
SEHK:2315 Stok Raporu
Biocytogen Pharmaceuticals (Beijing) Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6 Biocytogen Pharmaceuticals (Beijing) yıllık ortalama 5.6% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 31.7% annual. Gelirler yılda ortalama 26.8% oranında büyüyor .
Anahtar bilgiler Biotechs Sektör Büyümesi 11.0% Gelir büyüme oranı 26.8% Özkaynak getirisi -32.8% Net Marj -30.5% Son Kazanç Güncellemesi 30 Jun 2024
Yakın geçmiş performans güncellemeleri
First half 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.48 loss in 1H 2023) Sep 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Q2, 2024 Results on Aug 28, 2024 Aug 16
Full year 2023 earnings released: CN¥0.96 loss per share (vs CN¥1.58 loss in FY 2022) Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
First half 2023 earnings released: CN¥0.48 loss per share (vs CN¥0.73 loss in 1H 2022) Aug 30
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Tüm güncellemeleri göster
First half 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.48 loss in 1H 2023) Sep 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Q2, 2024 Results on Aug 28, 2024 Aug 16
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment? May 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 28
Full year 2023 earnings released: CN¥0.96 loss per share (vs CN¥1.58 loss in FY 2022) Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
New minor risk - Share price stability Feb 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company Dec 13
New minor risk - Share price stability Oct 06
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs Sep 15
Forecast to breakeven in 2025 Aug 31
First half 2023 earnings released: CN¥0.48 loss per share (vs CN¥0.73 loss in 1H 2022) Aug 30
New minor risk - Profitability Aug 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth Aug 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Forecast to breakeven in 2025 Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Launches Rennano Mouse, Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery Dec 30
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces FDA Clearance of IND Application for Bispecific Antibody YH008 Dec 19
Less than half of directors are independent Nov 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Management Appointments Nov 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Resignation of Huang Xiaolu as Non-Executive Director and A Member of the Strategy Development Committee Oct 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Present at Biojapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress Sep 28
First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021) Sep 27
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has completed an IPO in the amount of HKD 548.74937 million. Sep 01
Less than half of directors are independent Sep 01
Biocytogen Pharmaceuticals (Beijing) nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi SEHK:2315 Gelir, gider ve kazançlar (CNY Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Jun 24 801 -244 347 388 31 Mar 24 759 -313 348 431 31 Dec 23 717 -383 349 474 30 Sep 23 674 -451 339 547 30 Jun 23 632 -519 329 619 31 Mar 23 583 -561 321 659 31 Dec 22 534 -602 314 699 30 Sep 22 493 -585 283 687 30 Jun 22 453 -569 252 675 31 Mar 22 404 -557 241 617 31 Dec 21 355 -546 230 558 31 Dec 20 254 -217 277 276
Kaliteli Kazançlar: 2315 şu anda kârlı değil.
Büyüyen Kar Marjı: 2315 şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 2315 kârlı değildir, ancak son 5 yılda zararlarını yılda 5.6% oranında azaltmıştır.
Büyüme Hızlandırma: 2315 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: 2315 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 7.1% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: 2315 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi 'ne ( -32.76% ) sahiptir.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
